Stock listing

NASDAQ:PHAT Phathom Pharmaceuticals, Inc. Stock

Home listing (NASDAQ) of Phathom Pharmaceuticals, Inc.

Follow Phathom Pharmaceuticals, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PHAT

$4.66 USD -0.64 (-12.1%)

Close on Nov 20, 2026

Past year -67.5% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$4.62 – $5.15 USDNov 20, 2026
Volume
1.33M sharesNov 20, 2026
Market cap
$378.8M USDAt the close on Nov 20, 2026 · price × 81.29M shares outstanding
52-week range
$4.62 – $18.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$10.07M USDMedian day 1.33M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Phathom Pharmaceuticals, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PHAT · Home$4.66 USD-0.64 (-12.1%)1,330,427$5.03$5.145$4.615$5.30Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PHAT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$4.66-0.64-12.1%$5.03$5.145$4.6151,330,427
$5.30-0.20-3.6%$5.50$5.535$5.041,674,833
$5.50-0.38-6.5%$5.925$5.954$5.471,060,440
$5.88-0.18-3.0%$6.02$6.14$5.7651,118,057
$6.06-0.17-2.7%$6.24$6.24$5.781,509,711
$6.23-0.05-0.8%$6.21$6.376$6.101,087,524
$6.28+0.835+15.3%$5.45$6.315$5.411,570,634
$5.445+0.115+2.2%$5.26$5.55$5.151,506,615
$5.33+0.08+1.5%$5.455$5.49$5.181,938,582
$5.25+0.17+3.3%$5.26$5.305$5.041,770,845
$5.08-0.60-10.6%$5.70$5.70$5.0451,551,248
$5.68-0.06-1.0%$5.95$6.13$5.661,504,074
$5.74-0.175-3.0%$5.92$6.11$5.502,162,617
$5.915+0.175+3.0%$5.76$5.925$5.4952,812,512
$5.74-0.48-7.7%$6.32$6.32$5.591,618,521
$6.22-0.06-1.0%$7.00$7.00$5.713,843,346
$6.28+0.29+4.8%$5.94$6.43$5.852,080,738
$5.99+0.05+0.8%$5.945$6.18$5.8152,103,987
$5.94+0.20+3.5%$5.70$6.06$5.702,113,825
$5.74-1.27-18.1%$6.72$6.76$5.0154,863,900
$7.01-0.02-0.3%$7.04$7.217$6.965811,700
$7.03-0.28-3.8%$7.31$7.48$7.01784,200
$7.31+0.30+4.3%$7.04$7.40$6.96724,300
$7.01+0.09+1.3%$6.88$7.05$6.781,017,100
$6.92-0.58-7.7%$7.51$7.57$6.901,254,200
$7.50+0.10+1.4%$7.54$7.69$7.411,210,200
$7.40+0.40+5.7%$6.97$7.72$6.9181,721,100
$7.00-0.13-1.8%$7.14$7.16$6.861,947,200
$7.13-0.12-1.7%$7.25$7.285$7.031,013,700
$7.25+0.12+1.7%$7.13$7.30$7.015928,300
$7.13+0.32+4.7%$6.79$7.18$6.681,334,400
$6.81+0.03+0.4%$6.87$7.03$6.601,630,600
$6.78+0.08+1.2%$6.75$6.80$6.522,087,800
$6.70-0.22-3.2%$6.95$7.00$6.6451,104,700
$6.92-0.16-2.3%$7.20$7.23$6.821,683,800
$7.08-0.22-3.0%$7.47$7.47$7.081,059,700
$7.30-0.06-0.8%$7.40$7.50$7.19809,100
$7.36+0.01+0.1%$7.34$7.45$7.185657,200
$7.35+0.05+0.7%$7.30$7.41$7.151,690,900
$7.30+0.22+3.1%$7.10$7.38$7.0951,442,500
$7.08+0.095+1.4%$6.98$7.19$6.911,424,500
$6.985-0.775-10.0%$7.825$7.825$6.981,042,400
$7.76+0.31+4.2%$7.58$7.84$7.401,953,100
$7.45-0.03-0.4%$7.54$7.62$7.31898,900
$7.48-0.27-3.5%$7.63$7.763$7.4651,788,500
$7.75+0.06+0.8%$7.81$8.00$7.591,499,500
$7.69-0.47-5.8%$8.00$8.24$7.662,072,400
$8.16-0.52-6.0%$8.63$8.655$8.101,641,900
$8.68+0.32+3.8%$8.45$8.83$8.351,315,300
$8.36-0.01-0.1%$8.40$8.52$8.071,389,000
$8.37-0.30-3.5%$8.50$8.545$8.291,092,300
$8.67-0.76-8.1%$9.32$9.32$8.641,109,300
$9.43-0.07-0.7%$9.42$9.65$9.221,032,700
$9.50+0.45+5.0%$8.99$9.55$8.891,235,700
$9.05-0.21-2.3%$9.30$9.311$8.984663,100
$9.26-0.13-1.4%$9.45$9.73$9.05932,600
$9.39-0.18-1.9%$9.55$9.675$9.15885,000
$9.57+0.39+4.2%$9.17$9.695$9.041,211,500
$9.18+0.24+2.7%$8.89$9.305$8.782894,400
$8.94+0.17+1.9%$8.77$8.99$8.5451,047,100
$8.77-0.03-0.3%$8.78$8.865$8.571800,600
$8.80+0.14+1.6%$8.75$8.94$8.64748,600
$8.66-0.21-2.4%$8.88$8.92$8.51992,700
$8.87+0.27+3.1%$8.63$8.896$8.59979,200
$8.60-0.72-7.7%$9.25$9.30$8.401,405,600
Ticker
NASDAQ:PHAT
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Phathom Pharmaceuticals, Inc. news

Phathom Pharmaceuticals, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
24 in the last 12 months · 155 in all · newest Nov 19, 2026 · oldest 2019
Calls
12 calls with a replay · 12 with a transcript · latest Oct 29, 2026
Decks
14 decks · latest Jul 30, 2026

Where Phathom Pharmaceuticals, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PHAT · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PHATBOATSUnited StatesUSD

Valuation

EV/sales 1.3× against a median of 42.0×: the lowest of 6 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$359.8M USD
P/E
Loss
EV/sales
1.3×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
Negative equity
Gross margin
80.7%
Operating margin
−9.3%
Net margin
−30.2%
Debt to equity
Negative equity
Beta vs S&P 500
1.08

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Phathom Pharmaceuticals, Inc. · NASDAQ:PHATUS$378.8MUS$359.8Mn/a1.3×n/an/a−30.2%n/a1.08
Avalo Therapeutics, Inc. · NASDAQ:AVTXUS$390.9M−US$1.93Mn/an/an/a0.9×n/a0.0×1.25
Mezzion Pharma Co., Ltd. · KRX:140410US$388.6MUS$358.6Mn/a57.3×n/a13.4×−325.0%0.0×n/a
Beijing Luzhu Biotechnology Co., Ltd. Class H · HKEX:2480US$388.3MUS$369.0Mn/an/an/a4.3×n/a0.4×n/a
Hanx Biopharmaceuticals (Wuhan) Co. Ltd. Class H · HKEX:3378US$387.5MUS$315.9Mn/an/an/a4.1×n/a0.1×n/a
Qurient Co., Ltd. · KRX:115180US$386.1MUS$370.1Mn/a70.5×n/a30.2×−543.0%0.8×n/a
Opus Genetics, Inc. · NASDAQ:IRDUS$385.7MUS$332.3Mn/a42.0×n/a10.0×n/a0.9×1.01
Eupraxia Pharmaceuticals, Inc. · TSX:EPRXUS$384.2MUS$252.6Mn/an/an/a2.9×n/a0.0×1.53
Hinova Pharmaceuticals, Inc. Class A · SSE:688302US$382.0MUS$286.5Mn/a23.0×n/a2.6×−167.3%0.1×n/a
Rezolute, Inc. · NASDAQ:RZLTUS$379.2MUS$289.9Mn/an/an/a4.4×n/a0.0×1.28
Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509US$370.7MUS$380.6M4.5×2.5×4.2×2.9×53.3%0.8×n/a
Median of the othersUS$385.9MUS$324.1M4.5×42.0×4.2×4.2×−246.2%0.1×1.27

Forecasts

8 strong buy · 2 buy · 1 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
20.05 USD · Analysts' mean
EPS, year to Dec 2026
-0.046 · 5 analysts
Revenue, year to Dec 2026
315M · 9 analysts

Team and board

Officers

OfficerRole
Asit ParikhPresident & Chief Executive Officer, MOMA Therapeutics
Steven BastaPresident & Chief Executive Officer
Sanjeev NarulaChief Financial and Business Officer
Mark StenhouseChief Operating Officer, Prometheus Biosciences
Anne Marie CookChief Legal Officer and Corporate Secretary
Bill ApreaSenior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer
Jay BuchananSenior Vice President, Manufacturing & Supply Chain
Jonathan BentleySenior Vice President, Head of Sales, Operations, & Training
Mark DevlinSenior Vice President, Market Access
Robert BreedloveVice President, Finance & Principal Accounting Officer
Aditya KohliCo-Founder, Phathom
Azmi NabulsiCo-Founder, Phathom
David SocksCo-Founder, Phathom
Eckhard LeifkeChief Medical Officer
Paul CocjaChief People Officer
Tadataka YamadaCo-Founder and Late Chairman, Phathom

Board

DirectorRole
Tadataka YamadaCo-Founder and Late Chairman, Phathom
David SocksCo-Founder, Phathom
Heidi KunzDirector
Michael ColaDirector

Events

Results days

QuarterResultsShare move
Q3 2026Oct 29, 2026 · Before open−1.0%
Q2 2026Jul 30, 2026 · Before open−22.4%
Q1 2026May 12, 2026+2.8%
Q4 2025Feb 26, 2026 · Before open+10.1%
Q3 2025Oct 30, 2025 · Before open−1.6%
Q2 2025Aug 7, 2025 · Before open+8.3%
Q1 2025May 7, 2025 · Before open0.0%
Q4 2024Mar 6, 2025 · Before open−3.0%
Q3 2024Nov 7, 2024 · Before open+2.8%
Q2 2024Aug 8, 2024 · Before open+8.7%
All 20 quarters
QuarterResultsShare move
Q1 2024May 9, 2024 · Before open−0.1%
Q4 2023Mar 7, 2024 · Before open−6.6%
Q3 2023Nov 9, 2023 · Before open+0.5%
Q2 2023Aug 10, 2023 · Before open+3.7%
Q1 2023May 10, 2023 · Before open+3.7%
Q4 2022Feb 28, 2023 · Before open−11.8%
Q3 2022Nov 8, 2022 · After close−7.5%
Q2 2022Aug 2, 2022 · Before open−28.8%
Q1 2022May 10, 2022 · Before open−8.1%
Q4 2021Mar 1, 2022 · After close+2.0%

Open Events

Decks

DeckKindSlidesDate
Q2 2026 Earnings PresentationEarnings15 slidesJul 30, 2026
Investor Presentation (July 2026)Investor deck35 slidesJuly 2026
Q1 2026 Earnings PresentationEarnings16 slidesApr 30, 2026
FY2025 Earnings PresentationEarnings15 slidesFebruary 2026
Q3 2025 Earnings PresentationEarnings14 slidesOct 30, 2025
Q2 2025 Earnings PresentationEarnings14 slidesAug 7, 2025
Q1 2025 Earnings PresentationEarnings13 slidesMay 1, 2025
Q4 2024 Earnings PresentationEarnings22 slidesMar 6, 2025
Q3 2024 Earnings PresentationEarnings21 slidesNov 7, 2024
Technical Presentation (October 2024)Technical10 slidesOctober 2024
All 14 decks
DeckKindSlidesDate
Q1 2024 Earnings PresentationEarnings22 slidesMay 13, 2024
Technical Presentation (May 2024)Technical23 slidesMay 2024
Q4 2023 Earnings PresentationEarnings17 slidesMar 7, 2024
Fact Sheet (August 2022)Fact sheet2 slidesAugust 2022

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Update: about US$130M · US$16 a share · Guggenheim Securities +5
Dealers: Guggenheim Securities (co-lead), Cantor (co-lead), Raymond James, Needham & Company, H.C. Wainwright & Co., Craig-Hallum
Use of proceeds: General corporate purposes, including working capital and commercialization and research and development expenses
Jan 8, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$19.00 a share on Oct 24, 2019.

Price
US$19.00 a share
Shares offered
9,563,157 shares of common stock
Offering size
US$181.7 million
Underwriters' option
Up to 1,434,473 more shares
Underwriters
Goldman Sachs & Co. LLC, Jefferies, Evercore ISI, Needham & Company · In the order on the cover

Steps

StepWhen
Draft sent to the SEC in confidenceJul 26, 2019
Filed publiclySep 30, 2019
Amended onceOct 15, 2019
Shares registered with an exchangeOct 16, 2019
Declared effective by the SECOct 24, 2019
Final prospectus, with the priceOct 28, 2019

Open IPO · From the cover of the final prospectus (424B4) filed Oct 28, 2019

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Revenue175.1M55.3M682.0K0
Cost of revenue22.6M7.97M167.0K0
Gross profit152.5M47.3M515.0K0
Research and development32.8M34.1M49.9M71.4M72.3M98.1M20.4M20.0K
Selling, general and administrative279.7M290.7M117.9M101.0M
Operating income-160.0M-277.5M-167.3M-172.4M-135.1M-125.7M-106.2M-1.23M
Depreciation and amortization633.0K795.0K575.0K620.0K521.0K323.0K8.00K0
EBITDA-159.4M-276.7M-166.7M-171.8M-134.6M-125.3M-106.2M-1.23M
Interest expense68.1M72.0M42.0M27.3M6.79M4.58M4.18M13.0K
Income before tax-221.2M-334.3M
Income tax00000000
Net income-221.2M-334.3M-201.6M-197.7M-143.9M-129.1M-255.1M-1.29M
Earnings per share, basic-3.03-5.29-3.93-5.05-3.89-3.88-22.45-0.21
Earnings per share, diluted-3.03-5.29-3.93-5.05-3.89-3.88-22.45-0.21

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash and equivalents130.0M297.3M381.4M155.4M183.3M287.5M243.8M879.0K
Receivables78.1M38.8M1.64M0
Inventory5.52M3.21M1.21M0
Current assets229.0M360.1M397.4M160.5M186.5M291.4M255.6M902.0K
Property, plant and equipment1.06M1.48M2.15M1.21M650.0K986.0K463.0K
Total assets259.1M378.3M413.8M164.8M189.4M295.1M257.2M902.0K
Accounts payable4.98M10.5M12.6M10.00M5.15M16.8M699.0K55.0K
Current liabilities132.0M85.7M38.8M26.2M18.9M55.5M3.75M2.19M
Long-term debt209.1M201.4M137.8M95.3M89.7M39.6M22.8M
Total debt209.1M201.4M137.8M95.3M89.7M47.0M22.8M
Total liabilities697.3M631.9M486.6M239.6M117.3M100.8M29.2M2.19M
Shareholders' equity-438.2M-253.6M-72.8M-74.8M72.2M194.3M228.0M-1.29M
Shares outstanding71.4M68.5M58.0M41.5M30.5M28.5M24.7M6.76M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations-166.8M-266.8M-137.6M-146.5M-148.5M-69.7M-36.5M-1.02M
Capital spending-229.0K-135.0K-1.63M-1.04M-328.0K-1.04M-132.0K
Free cash flow-167.0M-266.9M-139.2M-147.6M-148.8M-70.7M-36.6M
Cash from investing-229.0K-135.0K-1.63M-1.04M-328.0K-1.04M-25.3M
Cash from financing-288.0K182.8M367.6M120.0M44.7M114.5M304.6M1.90M
Change in cash-167.3M-84.1M228.4M-27.5M-104.1M43.7M242.9M879.0K

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 18, 2026Management or board changeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 10, 2026Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 2, 2026Big-stake noticeSEC
10-Q · Quarterly reportOct 29, 2026Quarterly reportSEC
8-K · Current reportOct 29, 2026ResultsSEC
8-K · Current reportOct 26, 2026Current reportSEC
8-K · Current reportOct 23, 2026Current reportSEC
4 · Change in ownershipOct 8, 2026Insider tradeSEC
8-K · Current reportSep 29, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
10-Q · Quarterly reportJul 30, 2026Quarterly reportSEC
8-K · Current reportJul 30, 2026ResultsSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 20, 2026Big-stake noticeSEC
4 · Change in ownershipJul 16, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Current reportSEC
4 · Change in ownershipMay 27, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
4 · Change in ownershipMay 21, 2026Insider tradeSEC
8-K · Current reportMay 21, 2026Meeting outcomeSEC
10-Q · Quarterly reportApr 30, 2026Quarterly reportSEC
8-K · Current reportApr 30, 2026ResultsSEC
DEFA14A · Additional proxy materialApr 7, 2026Meeting noticeSEC
ARS · Annual report to shareholdersApr 7, 2026Annual reportSEC
DEF 14A · Proxy statementApr 7, 2026Meeting noticeSEC
S-8 · Registration statement for employee plansMar 27, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeMar 12, 2026Big-stake noticeSEC
4 · Change in ownershipMar 11, 2026Insider tradeSEC
4 · Change in ownershipMar 3, 2026Insider tradeSEC
10-K · Annual reportFeb 26, 2026Annual reportSEC
8-K · Current reportFeb 26, 2026ResultsSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipFeb 12, 2026Insider tradeSEC
4 · Change in ownershipJan 27, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJan 27, 2026Big-stake noticeSEC
4 · Change in ownershipJan 23, 2026Insider tradeSEC
4 · Change in ownershipJan 15, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Current reportSEC
424B5 · ProspectusJan 8, 2026Offer documentSEC
424B5 · ProspectusJan 7, 2026Offer documentSEC
8-K · Current reportJan 7, 2026ResultsSEC
S-3ASR · Registration statementJan 7, 2026Offer documentSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipJan 2, 2026Insider tradeSEC
4 · Change in ownershipDec 23, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 19, 2025Insider tradeSEC
4 · Change in ownershipDec 2, 2025Insider tradeSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedNov 4, 2025Big-stake noticeSEC
8-K · Current reportNov 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 3, 2025Big-stake noticeSEC
10-Q · Quarterly reportOct 30, 2025Quarterly reportSEC
8-K · Current reportOct 30, 2025ResultsSEC
8-K · Current reportOct 27, 2025Current reportSEC
4/A · Change in ownership, amendedOct 8, 2025Insider tradeSEC
4 · Change in ownershipOct 7, 2025Insider tradeSEC
3 · Initial statement of ownershipOct 7, 2025Insider tradeSEC
8-K · Current reportOct 6, 2025Management or board changeSEC
4 · Change in ownershipSep 26, 2025Insider tradeSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 28, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 25, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedAug 20, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 13, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 7, 2025Quarterly reportSEC
8-K · Current reportAug 7, 2025ResultsSEC
4 · Change in ownershipJul 18, 2025Insider tradeSEC
4 · Change in ownershipJun 24, 2025Insider tradeSEC
3 · Initial statement of ownershipJun 24, 2025Insider tradeSEC
8-K · Current reportJun 16, 2025Current reportSEC
8-K · Current reportJun 9, 2025Meeting outcomeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 9, 2025Big-stake noticeSEC
8-K · Current reportJun 6, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 6, 2025Big-stake noticeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
4 · Change in ownershipJun 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJun 4, 2025Big-stake noticeSEC
4 · Change in ownershipMay 23, 2025Insider tradeSEC
4 · Change in ownershipMay 21, 2025Insider tradeSEC
4 · Change in ownershipMay 15, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedMay 13, 2025Big-stake noticeSEC
4 · Change in ownershipMay 13, 2025Insider tradeSEC
4 · Change in ownershipMay 8, 2025Insider tradeSEC
3 · Initial statement of ownershipMay 6, 2025Insider tradeSEC
10-Q · Quarterly reportMay 1, 2025Quarterly reportSEC
8-K · Current reportMay 1, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedApr 24, 2025Big-stake noticeSEC
ARS · Annual report to shareholdersApr 23, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 23, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 23, 2025Meeting noticeSEC
4 · Change in ownershipApr 16, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 16, 2025Insider tradeSEC
8-K · Current reportApr 16, 2025Management or board changeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
3 · Initial statement of ownershipApr 3, 2025Insider tradeSEC
S-8 · Registration statement for employee plansApr 3, 2025Offer documentSEC
8-K · Current reportApr 1, 2025Management or board changeSEC
4 · Change in ownershipMar 21, 2025Insider tradeSEC
4 · Change in ownershipMar 17, 2025Insider tradeSEC
S-8 · Registration statement for employee plansMar 6, 2025Offer documentSEC
8-K · Current reportMar 6, 2025ResultsSEC
10-K · Annual reportMar 6, 2025Annual reportSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipMar 3, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipJan 23, 2025Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 20, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
8-K · Current reportDec 11, 2024Current reportSEC
SC 13G · Big-stake noticeNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 7, 2024Quarterly reportSEC
8-K · Current reportNov 7, 2024ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 5, 2024Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 5, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeNov 4, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeOct 21, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedAug 22, 2024Big-stake noticeSEC
8-K · Current reportAug 19, 2024Current reportSEC
424B5 · ProspectusAug 19, 2024Offer documentSEC
FWP · Free writing prospectusAug 19, 2024Offer documentSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 8, 2024ResultsSEC
8-K · Current reportJul 18, 2024Current reportSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
4 · Change in ownershipJul 17, 2024Insider tradeSEC
UPLOAD · Letter from the SECJun 25, 2024Other filingsSEC
10-K/A · Annual report, amendedJun 14, 2024Annual reportSEC
10-Q/A · Quarterly report, amendedJun 14, 2024Quarterly reportSEC
CORRESP · Letter to the SECJun 14, 2024Other filingsSEC
SC 13D/A · Big-stake notice, amendedJun 6, 2024Big-stake noticeSEC
UPLOAD · Letter from the SECJun 6, 2024Other filingsSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 31, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
4 · Change in ownershipMay 24, 2024Insider tradeSEC
8-K · Current reportMay 24, 2024Meeting outcomeSEC
10-Q · Quarterly reportMay 9, 2024Quarterly reportSEC
8-K · Current reportMay 9, 2024ResultsSEC
DEFA14A · Additional proxy materialApr 12, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 12, 2024Meeting noticeSEC
ARS · Annual report to shareholdersApr 12, 2024Annual reportSEC
4 · Change in ownershipApr 10, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedApr 10, 2024Big-stake noticeSEC
SC 13D/A · Big-stake notice, amendedApr 1, 2024Big-stake noticeSEC
4 · Change in ownershipMar 26, 2024Insider tradeSEC
10-K · Annual reportMar 7, 2024Annual reportSEC
8-K · Current reportMar 7, 2024ResultsSEC
8-K · Current reportFeb 13, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedFeb 12, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 9, 2024Big-stake noticeSEC
3 · Initial statement of ownershipJan 26, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedJan 26, 2024Big-stake noticeSEC
4 · Change in ownershipJan 25, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedJan 25, 2024Big-stake noticeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
4 · Change in ownershipJan 22, 2024Insider tradeSEC
8-K · Current reportDec 15, 2023Current reportSEC
8-K · Current reportDec 14, 2023Material contractSEC
8-K · Current reportDec 6, 2023Current reportSEC
8-K · Current reportNov 28, 2023Current reportSEC
4 · Change in ownershipNov 21, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveNov 20, 2023Other filingsSEC
CORRESP · Letter to the SECNov 15, 2023Other filingsSEC
UPLOAD · Letter from the SECNov 15, 2023Other filingsSEC
S-3 · Registration statementNov 9, 2023Offer documentSEC
10-Q · Quarterly reportNov 9, 2023Quarterly reportSEC
8-K · Current reportNov 9, 2023ResultsSEC
4 · Change in ownershipNov 8, 2023Insider tradeSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
4 · Change in ownershipNov 3, 2023Insider tradeSEC
8-K · Current reportNov 1, 2023Current reportSEC
8-K · Current reportOct 30, 2023Current reportSEC
8-K · Current reportSep 26, 2023Current reportSEC
8-K · Current reportAug 21, 2023Current reportSEC

This page holds 200 of 497 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Phathom Pharmaceuticals, Inc.’s releases · as of Oct 27, 2026

Common shares
81,291,520
Fully diluted
81,291,520

Fully diluted

LineSharesAs of
Common shares81,291,520Oct 27, 2026

Share count over time

CountShares
Oct 27, 202681,291,520

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Frazier Life Sciences Management, L.P.12.5M15.3%US$91MSep 30, 2026
Medicxi Ventures Management (Jersey) Ltd7.46M9.2%US$54.5MSep 30, 2026
BlackRock5.25M6.5%US$38.3MSep 30, 2026
Vanguard3.87M4.8%US$28.2MSep 30, 2026
Carlyle Group Inc.3.5M4.3%US$25.5MSep 30, 2026
Wasatch Advisors LP2.94M3.6%US$21.5MSep 30, 2026
Franklin Templeton2.41M3.0%US$13.7MSep 30, 2026
Millennium2.4M3.0%US$17.5MSep 30, 2026
GW&K Investment Management, LLC2.13M2.6%US$15.5MSep 30, 2026
683 Capital Management, LLC2M2.5%US$14.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street2M2.5%US$14.6MSep 30, 2026
NEA Management Company, LLC1.96M2.4%US$14.3MSep 30, 2026
Catalys Pacific, LLC1.88M2.3%US$13.7MSep 30, 2026
Nomura1.84M2.3%US$13.4MSep 30, 2026
Point72 Asset Management, L.P.1.5M1.8%US$11MSep 30, 2026
Geode Capital1.33M1.6%US$9.74MSep 30, 2026
Propel Bio Management, LLC1.11M1.4%US$8.07MSep 30, 2026
Ameriprise968K1.2%US$7.07MSep 30, 2026
Goldman Sachs895K1.1%US$6.53MSep 30, 2026
Trexquant Investment LP856K1.1%US$6.25MSep 30, 2026
Ensign Peak Advisors, Inc814K1.0%US$5.94MSep 30, 2026
HSBC813K1.00%US$5.94MSep 30, 2026
Schwab490K0.60%US$3.58MSep 30, 2026
Northern Trust468K0.58%US$3.41MSep 30, 2026
UBS445K0.55%US$3.25MSep 30, 2026
Two Sigma435K0.53%US$3.17MSep 30, 2026
StepStone Group LP422K0.52%US$3.08MSep 30, 2026
Hennion & Walsh Asset Management, Inc.392K0.48%US$2.86MSep 30, 2026
Woodline Partners LP369K0.45%US$2.7MSep 30, 2026
Citadel344K0.42%US$2.51MSep 30, 2026
Jones Hill Capital LP277K0.34%US$2.02MSep 30, 2026
JPMorgan274K0.34%US$2.01MSep 30, 2026
XTX Topco Ltd250K0.31%US$1.82MSep 30, 2026
Simplify Asset Management Inc.249K0.31%US$1.82MSep 30, 2026
D. E. Shaw & Co., Inc.242K0.30%US$1.77MSep 30, 2026
Jacobs Levy Equity Management, Inc228K0.28%US$1.66MSep 30, 2026
BNP Paribas197K0.24%US$1.44MSep 30, 2026
NewEdge Advisors, LLC189K0.23%US$1.38MSep 30, 2026
Wellington180K0.22%US$1.32MSep 30, 2026
Diadema Partners LP180K0.22%US$1.31MSep 30, 2026
Virtus Investment Advisers, LLC163K0.20%US$1.19MSep 30, 2026
Schonfeld Strategic Advisors LLC160K0.20%US$1.17MSep 30, 2026
Bank of America157K0.19%US$1.15MSep 30, 2026
BNY156K0.19%US$1.14MSep 30, 2026
Squarepoint Ops LLC141K0.17%US$1.03MSep 30, 2026
Nuveen134K0.16%US$979KSep 30, 2026
Wells Fargo121K0.15%US$886KSep 30, 2026
Profund Advisors LLC121K0.15%US$886KSep 30, 2026
Quantbot Technologies LP120K0.15%US$874KSep 30, 2026
Morgan Stanley107K0.13%US$784KSep 30, 2026

This page holds 50 of 153 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Invesco Global Fund2.34M2.9%US$20.5MJul 31, 2026
Vanguard Total Stock Market Index Fund2.01M2.5%US$21.8MJun 30, 2026
iShares Russell 2000 ETF1.28M1.6%US$13.9MJun 30, 2026
Nomura Small Cap Growth Fund989K1.2%US$10.7MJun 30, 2026
Strategic Advisers U.S. Total Stock Fund966K1.2%US$9.27MMay 31, 2026
Franklin Small Cap Growth Fund827K1.0%US$7.24MJul 31, 2026
Wasatch Micro Cap Fund807K0.99%US$8.75MJun 30, 2026
Vanguard Extended Market Index Fund587K0.72%US$6.36MJun 30, 2026
Fidelity Small Cap Index Fund536K0.66%US$4.69MJul 31, 2026
Franklin Biotechnology Discovery Fund507K0.62%US$4.44MJul 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Wasatch Ultra Growth Fund462K0.57%US$5.01MJun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF420K0.52%US$4.55MJun 30, 2026
iShares Biotechnology ETF401K0.49%US$4.36MJun 30, 2026
Invesco V.I. Global Fund356K0.44%US$3.86MJun 30, 2026
JNL/Invesco Global Growth Fund337K0.42%US$3.75MMar 31, 2026
iShares Russell 2000 Value ETF333K0.41%US$3.61MJun 30, 2026
Invesco Global Equity Portfolio276K0.34%US$3MJun 30, 2026
AMG GW&K Small Cap Growth Fund260K0.32%US$2.28MJul 31, 2026
Fidelity Extended Market Index Fund255K0.31%US$2.45MMay 31, 2026
Simplify Propel Opportunities ETF249K0.31%US$2.7MJun 30, 2026
Vanguard Russell 2000 Index Fund238K0.29%US$2.29MMay 31, 2026
Schwab U.S. Small-Cap ETF237K0.29%US$2.27MMay 31, 2026
AMG GW&K Small Cap Value Fund210K0.26%US$2.28MJun 30, 2026
Nomura VIP Small Cap Growth Series192K0.24%US$2.09MJun 30, 2026
Invesco Health Care Fund185K0.23%US$1.62MJul 31, 2026
MML VIP Invesco Global Fund178K0.22%US$1.93MJun 30, 2026
iShares Micro-Cap ETF165K0.20%US$1.79MJun 30, 2026
SFT Nomura Small Cap Growth Fund163K0.20%US$1.77MJun 30, 2026
Vanguard Explorer Fund152K0.19%US$1.33MJul 31, 2026
Vanguard Health Care Index Fund140K0.17%US$1.34MMay 31, 2026
EQ/Invesco Global Portfolio138K0.17%US$1.5MJun 30, 2026
iShares U.S. Pharmaceuticals ETF133K0.16%US$1.44MJun 30, 2026
iShares Russell 2000 Growth ETF133K0.16%US$1.44MJun 30, 2026
Virtus Biotech Etf131K0.16%US$1.15MJul 31, 2026
Schwab Small-Cap Index Fund119K0.15%US$1.04MJul 31, 2026
Fidelity Total Market Index Fund92,7520.11%US$889KMay 31, 2026
Master Small Cap Index Series91,9370.11%US$998KJun 30, 2026
iShares Core S&P Total U.S. Stock Market ETF78,6500.10%US$853KJun 30, 2026
Vanguard U.S. Momentum Factor ETF78,3520.10%US$751KMay 31, 2026
AQR Small Cap Multi-Style Fund76,7660.09%US$833KJun 30, 2026
Fidelity Series Total Market Index Fund75,7540.09%US$726KMay 31, 2026
EQ/Global Equity Managed Volatility Portfolio67,4300.08%US$732KJun 30, 2026
Nuveen Small Cap Blend Index Fund65,2610.08%US$571KJul 31, 2026
EQ/2000 Managed Volatility Portfolio54,9610.07%US$596KJun 30, 2026
AMG GW&K Small/Mid Cap Growth Fund54,2660.07%US$475KJul 31, 2026
Nuveen Equity Index Fund54,0240.07%US$473KJul 31, 2026
Vanguard Strategic Small-Cap Equity Fund51,8930.06%US$563KJun 30, 2026
Goldman Sachs Small Cap Value Insights Fund51,3030.06%US$449KJul 31, 2026
Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF49,5520.06%US$475KMay 31, 2026
Fidelity Small Cap Value Index Fund48,6990.06%US$528KJun 30, 2026

This page holds 50 of 159 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
James N. Topper7.40%6.01MOct 29, 2026Schedule 13D
BlackRock, Inc.5.50%4.38MJun 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
James N Topper
Other companies: Attovia Therapeutics, Inc. (Director · Since at least Aug 4, 2026); NewAmsterdam Pharma Company N.V. (Director · Since at least Dec 29, 2023); Frazier Lifesciences Acquisition Corp (Chief Executive Officer, Director · Dec 8, 2020 – Dec 11, 2020 · Past); Entasis Therapeutics Holdings Inc (Director · Sep 25, 2018 – Jan 18, 2019 · Past); Aptinyx Inc (Director · Jun 20, 2018 – Mar 31, 2020 · Past); Allena Pharmaceuticals Inc (Director · Nov 1, 2017 – Nov 17, 2020 · Past); Alpine Immune Sciences Inc (Director · Jul 24, 2017 – May 18, 2024 · Past); AnaptysBio, Inc. (Director · Jan 25, 2017 – Jan 6, 2023 · Past); Sierra Oncology Inc (Director · Jul 15, 2015 – Feb 14, 2017 · Past); Portola Pharmaceuticals Inc (Director · May 21, 2013 – Jun 5, 2013 · Past); Amicus Therapeutics Inc (Director · Jun 15, 2010 – Jun 12, 2014 · Past)
Director · Since at least Oct 24, 2019
Theodore R Schroeder
Other companies: Cidara Therapeutics Inc (Director · Since at least Apr 14, 2015); Nabriva Therapeutics AG (Director · Jul 24, 2018 – Jan 29, 2023 · Past); Collegium Pharmaceutical, Inc. (Director · Jan 22, 2016 – May 20, 2020 · Past); Otonomy Inc (Director · Aug 28, 2015 – Jun 21, 2022 · Past); Hyperion Therapeutics Inc (Director · Aug 11, 2014 – May 7, 2015 · Past); Trius Therapeutics Inc (Director · Aug 2, 2010 – Sep 11, 2013 · Past); Cadence Pharmaceuticals Inc (President, CEO, Director · Oct 24, 2006 – Mar 19, 2014 · Past)
Director · Since at least Apr 16, 2025
Frank Karbe
Other companies: Cidara Therapeutics Inc (Chief Financial Officer · Since at least Feb 24, 2025); Better Therapeutics, Inc. (Chief Executive Officer, Director · Jul 5, 2022 – Dec 18, 2023 · Past); Aduro Biotech Inc (Director · Apr 18, 2019 – May 5, 2020 · Past); Myovant Sciences Ltd (Principal Fin'l & Accounting · Oct 26, 2016 – Jul 7, 2021 · Past); Arbutus Biopharma Corporation (Director · Dec 31, 2014 – Jun 21, 2017 · Past); Exelixis, Inc. (EVP and CFO · Dec 8, 2006 – Feb 15, 2014 · Past)
Director · Since at least Apr 25, 2022
Michael Cola
Other companies: Sage Therapeutics Inc (Director · Since at least Sep 11, 2014); Avalo Therapeutics, Inc. (Chief Executive Officer, Director · Feb 3, 2020 – Oct 1, 2021 · Past); Aevi Genomic Medicine LLC (Chief Executive Officer, Director · Sep 13, 2013 – Jun 9, 2020 · Past); Vanda Pharmaceuticals Inc. (Director · Jun 14, 2012 – Jun 13, 2019 · Past); NuPathe Inc. (Director · Sep 30, 2011 – Feb 21, 2014 · Past)
Director · Since at least Oct 24, 2019
Molly Henderson
Other companies: UroGen Pharma Ltd. (Chief Financial Officer · Oct 1, 2020 – Jan 31, 2022 · Past); Advaxis Inc (Executive Vice President & CFO · Jun 6, 2018 – May 4, 2020 · Past); Iovance Biotherapeutics, Inc. (CFO · Jun 8, 2015 – Jun 1, 2016 · Past); VirtualScopics Inc (Chief Business/Financial Off. · May 30, 2006 – Jan 29, 2013 · Past)
CFO and CBO · Apr 5, 2022 – Apr 7, 2025 · Past
Steven L Basta
Other companies: VYNE Therapeutics Inc. (Director · Since at least Jul 19, 2021); Viveve Medical, Inc. (Director · Sep 13, 2018 – Jan 3, 2023 · Past); Carbylan Therapeutics Inc (Director · Apr 8, 2015 – Aug 3, 2015 · Past); Bioform Medical Inc (Chief Executive Officer, Director · Nov 5, 2007 – Feb 16, 2010 · Past)
President and CEO, Director · Since at least Apr 1, 2025
Anne Marie Cook
Other companies: Sage Therapeutics Inc (SVP, GC & Secretary · Sep 16, 2015 – Aug 5, 2024 · Past); Aegerion Pharmaceuticals Inc (SVP, General Counsel · Dec 5, 2011 – Aug 4, 2015 · Past)
Chief Legal Officer and Corporate Secretary · Since at least Jun 23, 2025
David Socks
Other companies: Hillevax Inc (CFO & Chief Business Officer · Apr 28, 2022 – Apr 28, 2022 · Past); Cadence Pharmaceuticals Inc (SVP · Oct 24, 2006 – Jun 14, 2010 · Past)
Co-Founder, Phathom · Since at least Oct 24, 2019
Heidi Fields
Other companies: Agilent Technologies, Inc. (Director · Nov 23, 2022 – Mar 14, 2025 · Past); Icosavax Inc (Director · Jun 10, 2022 – Jun 6, 2023 · Past)
Director · Since at least May 25, 2022
Mark Stenhouse
Other companies: Prometheus Biosciences Inc (Chief Operating Officer · Mar 11, 2021 – Jun 16, 2023 · Past); EXACT Sciences Corporation (President, Cologuard · Apr 2, 2018 – Apr 2, 2020 · Past)
Chief Operating Officer, Prometheus Biosciences · Since at least Mar 17, 2020
All 30 people
PersonSeat
Sanjeev Narula
Other companies: Intra-Cellular Therapies Inc (Executive Vice President & CFO · Aug 12, 2024 – Apr 2, 2025 · Past); Viatris Inc. (Chief Financial Officer · Aug 6, 2020 – Mar 2, 2023 · Past)
Chief Financial and Business Officer · Since at least Oct 6, 2025
Todd P Branning
Other companies: NeuBase Therapeutics Inc (Chief Financial Officer · Jan 10, 2022 – Mar 16, 2023 · Past); Amneal Pharmaceuticals, Inc. (SVP and CFO · Jan 21, 2019 – Feb 27, 2020 · Past)
Chief Financial Officer · Jul 13, 2020 – Jan 28, 2021 · Past
Aditya Kohli
Other companies: Hillevax Inc (Director · Since at least Apr 28, 2022)
Co-Founder, Phathom · Since at least Oct 24, 2019
Terrie Curran
Other companies: Arcutis Biotherapeutics, Inc. (Director · Since at least Jun 14, 2024)
President and Chief Executive, Director · Nov 1, 2023 – Feb 27, 2025 · Past
Anthony J GuzzoVP, Chief Accounting Officer · Jun 4, 2021 – Jan 19, 2022 · Past
Asit ParikhPresident & Chief Executive Officer, MOMA Therapeutics · Since at least Dec 2, 2019
Azmi NabulsiCo-Founder, Phathom · Since at least Oct 24, 2019
Bill ApreaSenior Vice President, Chief Compliance Officer and Deputy Chief Legal Officer · Since at least Nov 4, 2026
Christopher W SlavinskyDirector · Oct 24, 2019 – Oct 24, 2019 · Past
Eckhard LeifkeChief Medical Officer · Since at least Apr 28, 2025
Frank KarbeCidara Therapeutics · May 21, 2026 – Oct 8, 2026 · Past
Heidi KunzDirector · Since at least Nov 4, 2026
Jay BuchananSenior Vice President, Manufacturing & Supply Chain · Since at least Nov 4, 2026
Jonathan BentleySenior Vice President, Head of Sales, Operations, & Training · Since at least May 1, 2025
Mark DevlinSenior Vice President, Market Access · Since at least Nov 4, 2026
Paul CocjaChief People Officer · Since at least Nov 4, 2026
Robert BreedloveVice President, Finance & Principal Accounting Officer · Since at least May 1, 2025
Steven BastaPresident & Chief Executive Officer · Since at least Jul 30, 2026
Tadataka YamadaCo-Founder and Late Chairman, Phathom · Since at least Apr 28, 2025
Ted SchroederSince at least May 1, 2025

Open People

Log in to ask 6ix AI your own questions about Phathom Pharmaceuticals, Inc.